ABSTRACT
Background: In order to
evaluate the role ofketoconazole in the prevention of ovarian hyperstimulation
syndrome (OHSS) in women with polycystic ovary syndrome (PCOS) undergoing
ovarian stimulation with gonadotropins, a prospective, randomized, double-blind,
placebo controlled study was done on one-hundred and nine PCOS women that had
been refeiTed to be treated by gonadotropins.
Methods: Alll09 women were
assigned for random allocation. Group A (50 patients) received two ampoules
ofhMG beginning on day 2 or 3 of the cycle and ketoconazole (50 mg/every 48
hours) starting on the first day ofhMG treatment. Group B (51 patients)
received the same protocol ofhMG combined with one tablet of placebo every 48
hours. Main outcome measures were follicular development, E2levels, and
pregnancy rate.
Results: The total number
ofhMG ampoules and duration oftreatment to attain ovarian stimulation was
higher in group A (p
Conclusion: Ketoconazole
has no effect in prevention of OHSS in PCOS patients undergoing ovarian
stimulation. It may however reduce the rate of folliculogenesis and
steroidogenesis.
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |